[NO AUDITS – TURN-KEY – PAYER CONTRACTS – FAST-GROWING – DEBT-FREE – GREAT LOCATION]

Overview
============
This turnkey, high-complexity CLIA laboratory in a major metro city in Texas has demonstrated robust growth over the past three years (~40% CAGR) under new ownership, driven by a strong management and sales team. The lab’s revenue tripled from $1.19M in 2022 to $3.56M in 2025, while EBITDA increased 2.7x from $268K to $718K over the same period.

The Lab excels at providing high-quality service and fast turnaround times for confirmatory drug and molecular testing. The owners operate multiple businesses and are looking to focus on other companies in their portfolio that require more attention. With the lab now on a strong growth trajectory and bringing in a strong management team, this presents an attractive opportunity for buyers in the diagnostic testing business looking to expand their reach by acquiring the lab in TX, which is in a favorable Novitas MAC for molecular testing. It is also ideal for buyers in the medical field seeking a lab with a strong foundation and solid growth potential.

LAB SERVICES
===============
Toxicology
– Comprehensive drug confirmation panels
– Pain management & behavioral health
– Automated sample prep and batch processing for high throughput

Molecular (PCR–based)
– Respiratory, urinary, and wound pathogens
– Infectious disease screening

FINANCIALS
---------------------------------------------------------------------------------
| Year__________________________ | _____ Revenue (USD)| ______ EBITDA (USD) |
| 2022 _________________________ | ___________1,188,000 | ___________ 268,000 |
| 2023 _________________________ | __________ 1,282,000 | ___________ 489,000 |
| 2024 _________________________ | __________ 3,116,000 | ___________ 912,000 |
| TTM (Sep 2025 _______________ | __________ 3,272,000 | ___________ 654,000 |
| 2025 (Projected from Sep25) _ | __________ 3,555,000 | ___________ 718,000 |
----------------------------------------------------------------------------------

OPPORTUNITY HIGHLIGHTS
==========================
– Established clinical lab in a major metro city with profitable operations and a strong growth trajectory
– Payor contract in place, including BCBS TX and several other Blues, some hard-to-get Medicaids
– Strong recurring revenue base from core toxicology and molecular clients
– Re-invested profits for growth. Revenue CAGR (2022–2025P): ~40%
– Stable gross margins supported by in-house testing and reduced send-outs
– Friendly Novitas MAC for Molecular testing
– Debt-free

ASKING PRICE
==============
Inviting offers.